Ixico (AIM:IXI) said its contracted order book remains 21% above the FY25 year-end level, even after two sponsors discontinued existing Huntington's disease (HD) programmes.
The AIM-listed neuroscience imaging and biomarker analytics company, which uses an AI-driven platform to support drug development and diagnostics in neurological disorders, said the discontinuations cut its order book by approximately £1.5 million over the next two financial years.
The setback follows a strong first half, in which Ixico secured £8.0 million of new HD programme awards from new and existing clients, as disclosed in its half-year results.
Ixico described programme descoping as a normal feature of clinical drug development, offset by newer pipeline opportunities across a broad range of neurology indications and its recently created "TechBio" channels.
The company said HD remains one of the most active and well-funded areas of neuroscience drug development, alongside Alzheimer's and Parkinson's disease.
The board confirmed its recently upgraded FY26 guidance and its FY27 revenue guidance remain unchanged, and continues to expect the company to meet or exceed market expectations.
